Opus Genetics (IRD) Cash from Operations Growth (1y) (2011 - 2026)
Opus Genetics (IRD) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 158.60% |
| 10 | Opus Genetics | 283.27 Mn | 223.27 Mn | - | -41.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.51% |
| Dec 31, 2025 | -32.20% |
| Sep 30, 2025 | -20.02% |
| Jun 30, 2025 | -40.83% |
| Mar 31, 2025 | -57.35% |
| Dec 31, 2024 | -263.54% |
| Sep 30, 2024 | -70.83% |
| Jun 30, 2024 | -837.31% |
| Mar 31, 2024 | -56.77% |
| Dec 31, 2023 | -84.20% |
| Sep 30, 2023 | 33.24% |
| Jun 30, 2023 | 125.96% |
| Mar 31, 2023 | 40.91% |
| Dec 31, 2022 | 609.94% |
| Sep 30, 2022 | -25.50% |
| Jun 30, 2022 | 11.99% |
| Mar 31, 2022 | -6.16% |
| Dec 31, 2021 | -29.55% |
| Sep 30, 2021 | -239.39% |
| Jun 30, 2021 | -564.82% |